Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have been given an average recommendation of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $80.00.
Several equities research analysts have commented on NGVT shares. Weiss Ratings upgraded shares of Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Wall Street Zen downgraded Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st.
Check Out Our Latest Research Report on Ingevity
Insider Buying and Selling at Ingevity
Hedge Funds Weigh In On Ingevity
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assetmark Inc. lifted its stake in shares of Ingevity by 9.6% during the 1st quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after purchasing an additional 139 shares during the period. Frazier Financial Advisors LLC purchased a new stake in shares of Ingevity in the second quarter valued at $37,000. Evolve Private Wealth LLC increased its stake in Ingevity by 10.2% in the first quarter. Evolve Private Wealth LLC now owns 5,946 shares of the company’s stock valued at $424,000 after purchasing an additional 549 shares during the last quarter. Lazard Asset Management LLC increased its stake in Ingevity by 6.3% in the first quarter. Lazard Asset Management LLC now owns 9,262 shares of the company’s stock valued at $660,000 after purchasing an additional 549 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in Ingevity during the second quarter worth about $45,000. Institutional investors and hedge funds own 91.59% of the company’s stock.
Ingevity Price Performance
Shares of NGVT opened at $71.53 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. The stock’s 50 day moving average is $71.61 and its two-hundred day moving average is $71.89. Ingevity has a twelve month low of $45.85 and a twelve month high of $79.29. The firm has a market capitalization of $2.46 billion, a PE ratio of 48.66 and a beta of 1.14.
Ingevity (NYSE:NGVT – Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The business had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Research analysts anticipate that Ingevity will post 5.4 earnings per share for the current year.
Ingevity Company Profile
Ingevity Corporation (NYSE: NGVT) is a specialty chemicals and materials company headquartered in North Charleston, South Carolina. The company develops products designed to improve environmental performance, enhance infrastructure and support industrial manufacturing.
Ingevity’s products include activated carbon technologies used in automotive evaporative-emissions control systems, as well as applications involving air and water purification. The company also produces specialty chemicals and materials used in pavement preservation, asphalt modification and other industrial applications.
Featured Stories
- Five stocks we like better than Ingevity
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
